Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)

Recruiting

• Conditions: Endocrine Tumor

• Registration Number: NCT03410394
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.

Detailed Description

The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.

Study Timeline

• Study Start: 2015-01-01
• Study First Submitted: 2018-01-10
• Study First Submitted QC: 2018-01-24
• Study First Posted: 2018-01-25
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-12
• Primary Completion: 2030-01-01
• Study Completion: 2030-01-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital

Exclusion Criteria

• unable to receive clear information
• refusal to sign the consent form

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Postoperative complications (endocrine surgical procedure)	12 months after surgical procedure	morbidity rate in percentage (%)

Secondary Outcome Measures

Name	Time	Method
PET scanning	Baseline	standardized uptake values (SUV tumor / SUV liver ratio)
Postoperative complications severity (endocrine surgical procedure)	12 months after surgical procedure	Dindo-Clavien classification in percentage (%)
CT imaging before endocrine surgical procedure (Tumor characteristics)	Baseline	Density in Hounsfield unit (HU)
Aldosterone plasma levels	Baseline and up to 12 months after surgical procedure	Aldosterone (in pmol/L)
Intraoperative systolic arterial pressure	Intraoperative	systolic arterial pressure (in mmHg)
Plasma free metanephrines	Baseline and up to 12 months after surgical procedure	metanephrines (in nmol/L)
Postoperative mortality (endocrine surgical procedure)	12 months after surgical procedure	mortality rate in percentage (%)
Bone mineral density	Baseline	dual-energy x-ray absorptiometry (DEXA) (in T-score unit)
Intraoperative diastolic arterial pressure	Intraoperative	diastolic arterial pressure (in mmHg)
Plasma renin activity	Baseline and up to 12 months after surgical procedure	Renin (in μIU/mL)
CT imaging before endocrine surgical procedure (Coronary artery score)	Baseline	CAC score in Agatston score unit (HU)
CT imaging before endocrine surgical procedure (Sarcopenia)	preoperative period	Evaluation of sarcopenia using L3 skeletal muscle index (in cm²/m²)
Parathormone plasma levels	Baseline and up to 12 months after surgical procedure	Parathormone (in pg/mL)

Trial Locations

Locations (1)

CHU Nancy; 🇫🇷 Vandœuvre-lès-Nancy, France